öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÐ¤½¨ÓÂ
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º886

ËùÊôԺУ£º¹ãÖÝÖÐÒ½Ò©´óѧ
ËùÊôԺϵ£º201»ù´¡Ò½Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼/²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º £¨ÖÐÎ÷Ò½½áºÏ£©Ö×Áö·ÀÖκͷÖ×ÓÒ©Àí
Ñо¿ÁìÓò£º £¨ÖÐÎ÷Ò½½áºÏ£©Ö×Áö·ÀÖκͷÖ×ÓÒ©Àí [ÊÕÆð]




¸öÈ˼òÊö :
Ф½¨Ó£¬¹ãÖÝÖÐÒ½Ò©´óѧÉúÎﻯѧ¸±½ÌÊÚ£¬²©µ¼£¬ÉúÎﻯѧºÍ·Ö×ÓÉúÎïѧ½ÌÑÐÊÒ¸±Ö÷ÈΡ£
1999ÄêÔÚÖÐɽ´óѧÉúÎﻯѧϵ»ñѧʿѧλ£»2002ÄêÔÚÖÐɽ´óѧÉúÎ﹤³ÌÑо¿ÖÐÐÄ»ñÒÅ´«Ñ§Ë¶Ê¿Ñ§Î»£»2009ÄêÔÚÖÐɽ´óѧҽѧԺ»ñµÃÒ©Àíѧ²©Ê¿Ñ§Î»¡£2014Ä기ÃÀ¹ú¿ÏËþ»ù´óѧ°©Ö¢Ñо¿ÖÐÐÄ´Óʲ©Ê¿ºó¹¤×÷¡£
¿ÆÑÐÍŶÓÁ¥ÊôÓÚ¹ãÖÝÖÐÒ½Ò©´óѧÉúÎﻯѧºÍ²¡ÀíѧʵÑéÊÒ£¬ÒÀÍлù´¡Ò½Ñ§ÔºÖÐÎ÷Ò½½áºÏÊ¡ÖصãʵÑéÊÒƽ̨£¬Ö÷ÒªÑо¿ÖÐÎ÷Ò½½áºÏÖ×Áö·ÀÖκͷÖ×ÓÒ©Àí¡£

¿ÆÑй¤×÷ :
Ö÷³Ö[1]Ö÷³Ö¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£ºCircEphB4¿¹¸Î°©Ð»úÖƼ°°×޼«´¼¶ÔÆäµÄµ÷¿ØÑо¿£¨No.**£»2018.01-2021.12£»60Íò)¡£
[2]Ö÷³Ö¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£ºCirc-EphB4ÔÚ¸Îϸ°û°©ÖеÄ×÷Óü°Æä·Ö×Ó»úÖÆ(No.2017A**£»2017.05-2020.05£»10Íò)¡£
[3]Ö÷³Ö¹ã¶«Ê¡½ÌÓýÌüÆÕͨ¸ßУÌØÉ«´´ÐÂÀàÏîÄ¿£ºCirc-EphB4ͨ¹ýϵ÷CCL20ÒÖÖƸÎϸ°û°©ÔöÖ³ºÍתÒƵÄÑо¿£¨10Íò£©
[4]Ö÷³Ö¸ßˮƽ´óѧ½¨ÉèרÏî¾­·Ñ£ºCircEphB4¿¹¸Î°©Ð»úÖƼ°°×޼«´¼¶ÔÆäµÄµ÷¿ØÑо¿£¨20Íò£©
[5]Ö÷³Ö¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£º°×޼«´¼Í¨¹ýmiR-330°ÐÏòµ÷¿ØMRP1ÓÕµ¼±ÇÑÊ°©·ÅÉäÔöÃôµÄÑо¿(£¨No.**£»2013.1-2016.12£»68Íò)¡£
[6]Ö÷³Ö½ÌÓý²¿¸ßµÈѧУ²©Ê¿Ñ§¿ÆµãרÏî¿ÆÑлù½ð£º°×޼«´¼ÓÕµ¼±ÇÑÊ°©·ÅÉäÔöÃôµÄ»úÖÆÑо¿(No.**012£»2013.1-2015.12£»4Íò)¡£
[7]Ö÷³Ö¹ã¶«Ê¡×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£ºmiR-30a°ÐÏòµ÷¿ØUSP22ÒÖÖƱÇÑÊ°©Ï¸°ûϸ°ûÉú³¤ÔöÖ³µÄÑо¿(No.S**05£»2012.10-2014.10£»3Íò)¡£
[8]Ö÷³Ö¹ã¶«Ê¡ÖÐÒ½Ò©¾Ö¿ÆÑпÎÌ⣺»¢ÕÈÖ÷Òª³É·Ö°×޼«´¼¼°»¢ÕÈÜÕ¶Ô±ÇÑÊ°©·ÅÉäÔöÃôµÄ»úÖÆÑо¿(No.**£»2012.10-2014.10£»0.5Íò)¡£½ü¼¸Äê·¢±íÂÛÎÄ
[1]TanY,WeiX,ZhangW,WangX,WangK,DuBandXiaoJ*£¨Í¨Ñ¶×÷Õߣ©.ResveratrolenhancestheradiosensitivityofnasopharyngealcarcinomacellsbydownregulatingE2F1.OncolRep.201737:1833-1841.
[2]XiaoJ,ZhangG,LiB,WuY,LiuX,TanYandDuB.DioscinaugmentsHSV-tk-mediatedsuicidegenetherapyformelanomabypromotingconnexin-basedintercellularcommunication.Oncotarget.20178(1):798-807.
[3]XiaoJ,LiY,ZhangW,JiangY,DuBandTanY.miR-34binhibitsnasopharyngealcarcinomacellproliferationbytargetingubiquitin-specificpeptidase22.OncoTargetsTher.20169:1525-1534.
[4]XiaoJ,QiuP,LaiX,HeP,WuY,DuB,TanY.Cyclin-dependentkinase1inhibitorRO3306promotesmitoticslippageinpaclitaxel-treatedHepG2cells.Neoplasma2014,61(1):41-7.
[5]XiaoJ,ZhangG,QiuP,LiuX,WuY,DuB,LiJ,ZhouJ,LiJ,TanY.TanshinoneIIAIncreasestheBystanderEffectofHerpesSimplexVirusThymidineKinase/GanciclovirGeneTherapyviaEnhancedGapJunctionalIntercellularCommunication.PLoSOne2013,8(7):e67662.
[6]XiaoJ,ZhangZ,ChenGG,ZhangM,DingY,FuJ,LiM,YunJP.Nucleophosmin/B23interactswithp21WAF1/CIP1andcontributestoitsstability.CellCycle2009,8(6):889-95.
[7]JafariN,ZhengQ,LiL,LiW,QiL,XiaoJ,GaoTandHuangC.S6K1-mediatedphosphorylationregulatesPhosphatidylinositol4-phosphate5-kinasetypeIgammadegradationandcellinvasion.JBiolChem.[Epubaheadofprint]
[8]WuGQ,ChaiKQ,ZhuXM,JiangH,WangX,XueQ,ZhengAH,ZhouHY,ChenY,ChenXC,XiaoJY,YingXH,WangFW,RuiT,LiaoYJ,XieD,etal.Anti-cancereffectsofcurcuminonlungcancerthroughtheinhibitionofEZH2andNOTCH1.Oncotarget.2016£¬7(18):26535-26
[9]WuGQ,WangX,ZhouHY,ChaiKQ,XueQ,ZhengAH,ZhuXM,XiaoJY,YingXH,WangFW,RuiT,XuLY,ZhangYK,LiaoYJ,XieD,LuLQ,etal.Evidencefortranscriptionalinterferenceinadual-luciferasereportersystem.SciRep.2015£¬5:17675.
[10]WangQQ,ZhangZY,XiaoJY,YiC,LiLZ,HuangY,YunJP.KnockdownofnucleophosmininducesS-phasearrestinHepG2cells.ChinJCancer.2011£¬30(12):853-60.